WithdrawnNot Applicable

Ovarian Damage in Young Premenopausal Women Undergoing Chemotherapy for Cancer

Stopped: slow accrual

United States0Started 2004-02

Plain-language summary

RATIONALE: Comparing results of diagnostic procedures, such as ultrasound, done before, during, and after chemotherapy may help doctors learn about the side effects of chemotherapy and help plan the best treatment. PURPOSE: This clinical trial is studying ovarian damage in young premenopausal women undergoing chemotherapy for cancer.

Who can participate

Age range14 Years – 35 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

DISEASE CHARACTERISTICS: * Diagnosis of cancer, including, but not limited to, any of the following: * Acute lymphocytic leukemia * Acute myeloid leukemia * Hodgkin's lymphoma * Must have primary disease with significant chance for long-term survival after therapy * Scheduled to receive chemotherapeutic agents known to be associated with ovarian failure, including any of the following: * Cyclophosphamide * Mechlorethamine hydrochloride * Busulfan * Procarbazine hydrochloride * Chlorambucil * Melphalan * Ifosfamide * Cisplatin * Carboplatin * Postmenarchal and premenopausal PATIENT CHARACTERISTICS: * Female * Weight ≤ 250 pounds * Not pregnant PRIOR CONCURRENT THERAPY: * No prior or concurrent total-body irradiation or radiotherapy to the pelvis * Concurrent bone marrow transplantation allowed * Concurrent oral contraception and/or gonadotropin releasing-hormone analogue allowed

What they're measuring

Incidence of ovarian damage after cytotoxic chemotherapy as determined by changes in ovarian volume, antral follicle count, and follicle-stimulating hormone, estradiol, and inhibin B levels

Timeframe: Ultrasound to measure the ovarian volume and count the number of antral follicles at baseline, 3 months after beginning cytotoxic chemotherapy, and at 6 months after completion of treatment. Patients undergo blood collection at the same time points.

Trial details

NCT IDNCT00402935

SponsorCase Comprehensive Cancer Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

View on ClinicalTrials.gov More Leukemia trials